366 related articles for article (PubMed ID: 28099914)
1. Advances in epigenetic glioblastoma therapy.
Lee DH; Ryu HW; Won HR; Kwon SH
Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
4. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
5. An update on the epigenetics of glioblastomas.
Ferreira WA; Pinheiro Ddo R; Costa Junior CA; Rodrigues-Antunes S; Araújo MD; Leão Barros MB; Teixeira AC; Faro TA; Burbano RR; Oliveira EH; Harada ML; Borges Bdo N
Epigenomics; 2016 Sep; 8(9):1289-305. PubMed ID: 27585647
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic pathways and glioblastoma treatment.
Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
[TBL] [Abstract][Full Text] [Related]
7. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme.
Li Q; Dong C; Cui J; Wang Y; Hong X
J Exp Clin Cancer Res; 2018 Oct; 37(1):265. PubMed ID: 30376874
[TBL] [Abstract][Full Text] [Related]
8. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells.
Grinshtein N; Rioseco CC; Marcellus R; Uehling D; Aman A; Lun X; Muto O; Podmore L; Lever J; Shen Y; Blough MD; Cairncross GJ; Robbins SM; Jones SJ; Marra MA; Al-Awar R; Senger DL; Kaplan DR
Oncotarget; 2016 Sep; 7(37):59360-59376. PubMed ID: 27449082
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Mechanisms Histone Deacetylase-Dependent Regulate the Glioblastoma Angiogenic Matrisome and Disrupt Endothelial Cell Behavior In Vitro.
Menezes A; Julião G; Mariath F; Ferreira AL; Oliveira-Nunes MC; Gallucci L; Evaristo JAM; Nogueira FCS; Pereira DA; Carneiro K
Mol Cell Proteomics; 2024 Mar; 23(3):100722. PubMed ID: 38272115
[TBL] [Abstract][Full Text] [Related]
10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
11. HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.
Herranz M; Padín-Iruegas ME; Martínez-Lago N; Losada SA; Raña-Díez P; Vázquez EB; Carrera JJ; Antúnez JR; Ruibal A; López-López R
Mol Neurobiol; 2016 Apr; 53(3):1802-1807. PubMed ID: 25752997
[TBL] [Abstract][Full Text] [Related]
12. New Directions in the Treatment of Glioblastoma.
Reitman ZJ; Winkler F; Elia AEH
Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Uddin MS; Mamun AA; Alghamdi BS; Tewari D; Jeandet P; Sarwar MS; Ashraf GM
Semin Cancer Biol; 2022 Aug; 83():100-120. PubMed ID: 33370605
[TBL] [Abstract][Full Text] [Related]
14. Zinc as a plausible epigenetic modulator of glioblastoma multiforme.
Balaji E V; Kumar N; Satarker S; Nampoothiri M
Eur J Pharmacol; 2020 Nov; 887():173549. PubMed ID: 32926916
[TBL] [Abstract][Full Text] [Related]
15. Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Preusser M; Lim M; Hafler DA; Reardon DA; Sampson JH
Nat Rev Neurol; 2015 Sep; 11(9):504-14. PubMed ID: 26260659
[TBL] [Abstract][Full Text] [Related]
16. The DNA methylome of glioblastoma multiforme.
Martinez R; Esteller M
Neurobiol Dis; 2010 Jul; 39(1):40-6. PubMed ID: 20064612
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology of glioma.
Marumoto T; Saya H
Adv Exp Med Biol; 2012; 746():2-11. PubMed ID: 22639155
[TBL] [Abstract][Full Text] [Related]
18. DNA repair mechanisms and their clinical impact in glioblastoma.
Erasimus H; Gobin M; Niclou S; Van Dyck E
Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma.
Chen N; Peng C; Li D
Front Immunol; 2022; 13():869307. PubMed ID: 35572545
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.
Yelton CJ; Ray SK
Neuroimmunol Neuroinflamm; 2018; 5():. PubMed ID: 30701185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
